Current Phase II investigational therapies for insomnia

Bibliography

• American Psychiatric Association. D-I: Primary insomnia Diagnostic and statistical manual of mental disorders. 4th edition. 2008. Available from: http://www.psychiatryonline.com/
   Google Scholar
• World Health Organization. I-: Nonorganic insomnia International classification of diseases. 10th edition. 2008. Available from: http://www.who.int/classifications/apps/icd/icd10online/
   Google Scholar
• Dement WC, Miles LE, Carskadon MA. “White paper” on sleep and aging. J Am Geriatr Soc 1982;30(1):25-50
   PubMed Web of Science ®Google Scholar
• Monane M. Insomnia in the elderly. J Clin Psychiatry 1992;53(Suppl):23-8
   PubMed Web of Science ®Google Scholar
• Leger D PB, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin 2008;24(1):307-17
   PubMed Web of Science ®Google Scholar
• Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the unites states: results of the 1991 national sleep foundation survey. II. Sleep 1999;22(Suppl 2):S354-8
   PubMed Web of Science ®Google Scholar
• Leger D, Guilleminault C, Bader G, et al. Medical and socio-professional impact of insomnia. Sleep 2002;25(6):625-9
   PubMed Web of Science ®Google Scholar
• Hauri PJ. Cognitive deficits in insomnia patients. Acta Neurol Belg 1997;97(2):113-17
   PubMed Web of Science ®Google Scholar
• Crenshaw C. Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav 1999;66(3):485-92
   PubMed Web of Science ®Google Scholar
• Szuba MP KJ, Dinges DF. Insomnia, principles and management. Cambridge University Press; Cambridge: 2003
   Google Scholar
• Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care 2009;15(Suppl):S6-13
   PubMed Web of Science ®Google Scholar
• Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262(11):1479-84
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30(2):213-18
   PubMed Web of Science ®Google Scholar
• Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. Eur Arch Psychiatry Clin Neurosci 1993;242(6):329-36
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. State of the science conference statement on manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep 2005;28(9):1049-57
   PubMed Web of Science ®Google Scholar
• Subramanian S, Surani S. Sleep disorders in the elderly. Geriatrics 2007;62(12):10-32
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Nutt DJ, Alford C, et al. British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24(11):1577-601
   PubMed Web of Science ®Google Scholar
• Shinomiya K, Inoue T, Utsu Y, et al. Hypnotic activities of chamomile and passiflora extracts in sleep-disturbed rats. Biol Pharm Bull 2005;28(5):808-10
   PubMed Web of Science ®Google Scholar
• Miroddi M, Calapai G, Navarra M, et al. Passiflora incarnata l.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol 2013;150(3):791-804
   PubMed Web of Science ®Google Scholar
• Roussin A, Bouyssi A, Pouche L, et al. Misuse and dependence on non-prescription codeine analgesics or sedative h1 antihistamines by adults: a cross-sectional investigation in france. PLoS One 2013;8(10):e76499
   PubMed Web of Science ®Google Scholar
• Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci 2005;26(11):578-86
   PubMed Web of Science ®Google Scholar
• Lim AS, Ellison BA, Wang JL, et al. Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer’s disease. Brain 2014;137(Pt 10):2847-61
   PubMedGoogle Scholar
• Lader MH. Abuse potential, tolerance and dependence on chronic anxiolytic treatment. In: Mendlewicz J, Racagni G, editors. Abuse and dependence of anxiolytics. 3. Karger; Basel: 1992. p. 46-54
   Google Scholar
• Reeder CE, Franklin M, Bramley TJ. Current landscape of insomnia in managed care. Am J Manag Care 2007;13(5 Suppl):S112-16
   PubMed Web of Science ®Google Scholar
• Kerr D, Ong J. Gaba-b receptors. Pharmacol Ther 1995;67(2):187-246
   PubMed Web of Science ®Google Scholar
• Carter CR, Kozuska JL, Dunn SM. Insights into the structure and pharmacology of GABA(a) receptors. Future Med Chem 2010;2(5):859-75
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE) L. Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical guideline 22. 2004. Available from: http://publication.snice.orguk/anxiety-amended-cg22
   Google Scholar
• Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther 2006;112(3):612-29
   PubMed Web of Science ®Google Scholar
• Nau SD, Lichstein KL. Insomnia: causes and treatments. In: Carney PR, Berry RB, Geyer JD, editors. Clinical sleep disorders. Lippincott Williams & Wilkins; Philadelphia: 2005. p. 157-90
   Google Scholar
• Zhang D, Tashiro M, Shibuya K, et al. Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol 2010;30(6):694-701
   PubMed Web of Science ®Google Scholar
• Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33(11):1553-61
   PubMed Web of Science ®Google Scholar
• Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30(11):1555-61
   PubMed Web of Science ®Google Scholar
• Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69(10):1557-64
   PubMed Web of Science ®Google Scholar
• Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011;34(10):1433-42
   PubMed Web of Science ®Google Scholar
• Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13(2):133-8
   PubMed Web of Science ®Google Scholar
• Alter P, Tontsch D, Grimm W. Doxepin-induced torsade de pointes tachycardia. Ann Intern Med 2001;135(5):384-5
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26(6):613-26
   PubMed Web of Science ®Google Scholar
• Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat 2008;4(1):69-79
   PubMedGoogle Scholar
• RAMELTEON: summary of product characteristics, FDA approved label 10.20.08 NDA 21-782, s-008/9/10. 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021782s008s009s010lbl.pdf
   Google Scholar
• Kohsaka M, Kanemura T, Taniguchi M, et al. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia. Expert Rev Neurother 2011;11(10):1389-97
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:51
   PubMed Web of Science ®Google Scholar
• Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin 2011;27(1):87-98
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Dumont M, Duffy JF, et al. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 1992;340(8825):933-6
   PubMed Web of Science ®Google Scholar
• Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309(6948):167
   PubMed Web of Science ®Google Scholar
• Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (circadin) for the treatment of insomnia. Expert Opin Pharmacother 2012;13(6):895-905
   PubMed Web of Science ®Google Scholar
• Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16(4):372-80
   PubMed Web of Science ®Google Scholar
• Agomelatine: Summary of product characteristics, Thymanax, approved EMA. 2009. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000916/human_med_001093.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009;18(10):1533-40
   PubMed Web of Science ®Google Scholar
• Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011;34(9):709-31
   PubMed Web of Science ®Google Scholar
• Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (vec-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373(9662):482-91
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Cano P, Jimenez-Ortega V, et al. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011;93(3):133-42
   PubMed Web of Science ®Google Scholar
• Dhillon S, Clarke M. Tasimelteon: first global approval. Drugs 2014;74(4):505-11
   PubMed Web of Science ®Google Scholar
• Tasimelteone: clinical assessment FDA. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205677s000lbl.pdf
   Google Scholar
• Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006;119(10):898-902
   PubMed Web of Science ®Google Scholar
• Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 2014;9:947-61
   PubMed Web of Science ®Google Scholar
• Jonas M, Garfinkel D, Zisapel N, et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003;12(1):19-24
   PubMed Web of Science ®Google Scholar
• Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35(2):125-30
   PubMed Web of Science ®Google Scholar
• Hiromasa S. [A new strategy of treatment of insomnia in the field of cardiology–potential of ramelteon]. Nihon Rinsho 2013;71(1):181-7
   PubMedGoogle Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell 1998;92(4):573-85
   PubMed Web of Science ®Google Scholar
• de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95(1):322-7
   PubMed Web of Science ®Google Scholar
• Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18(23):9996-10015
   PubMed Web of Science ®Google Scholar
• Selbach O, Haas HL. Hypocretins: the timing of sleep and waking. Chronobiol Int 2006;23(1-2):63-70
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-76
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98(4):437-51
   PubMed Web of Science ®Google Scholar
• Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010;87(5):593-600
   PubMed Web of Science ®Google Scholar
• Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(5):461-71
   PubMed Web of Science ®Google Scholar
• Robinson R. News from the AAN annual meeting: suvorexant for insomnia: a novel drug, but at what dose? Neurol Today 2014;14(12):5-6
   PubMedGoogle Scholar
• Suvorexant: FDA advisory committee. 2014. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374388.pdf
   Google Scholar
• Johnson KP, Malow BA. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol 2008;10(5):350-9
   PubMedGoogle Scholar
• EMA: Guideline on medicinal products for the treatment of insomnia. 2011. Available from: http://www.emaeuropa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351pdf
   Google Scholar
• Ohayon M, Zulley J. Correlates of global sleep dissatisfaction in the German population. Sleep 2001;24(7):780-7
   PubMed Web of Science ®Google Scholar
• Ustun TB, Privett M, Lecrubier Y, et al. Form, frequency and burden of sleep problems in general health care: a report from the WHO collaborative study on psychological problems in general health care. Eur Psychiatry 1996;11:5s-10s
   Web of Science ®Google Scholar
• Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166(16):1775-82
   PubMed Web of Science ®Google Scholar
• Reynolds CFIII, O’Hara R. DSM-5 sleep-wake disorders classification: overview for use in clinical practice. Am J Psychiatry 2013;170(10):1099-101
   PubMed Web of Science ®Google Scholar
• Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev 2010;14(1):9-15
   PubMed Web of Science ®Google Scholar
• Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010;14(1):19-31
   PubMed Web of Science ®Google Scholar
• Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, et al. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study. Sleep 2011;34(11):1487-92
   PubMed Web of Science ®Google Scholar
• Grandner MA, Jackson NJ, Pak VM, et al. Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res 2012;21(4):427-33
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30(2):213-18
   PubMed Web of Science ®Google Scholar
• Blackwell T, Yaffe K, Laffan A, et al. Associations of objectively and subjectively measured sleep quality with subsequent cognitive decline in older community-dwelling men: the MrOS sleep study. Sleep 2014;37(4):655-63
   PubMed Web of Science ®Google Scholar
• Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology–a bidirectional relationship. Nat Rev Neurol 2014;10(2):115-19
   PubMed Web of Science ®Google Scholar
• Paudel M, Taylor BC, Ancoli-Israel S, et al. Sleep disturbances and risk of depression in older men. Sleep 2013;36(7):1033-40
   PubMed Web of Science ®Google Scholar
• Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. Res Dev Disabil 2011;32(3):939-62
   PubMed Web of Science ®Google Scholar
• Mindell JA, Emslie G, Blumer J, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics 2006;117(6):e1223-32
   PubMed Web of Science ®Google Scholar
• Carr R, Wasdell MB, Hamilton D, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res 2007;43(4):351-9
   PubMed Web of Science ®Google Scholar
• Tordjman S, Najjar I, Bellissant E, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013;14(10):20508-42
   PubMed Web of Science ®Google Scholar
• Chaste P, Clement N, Botros HG, et al. Genetic variations of the melatonin pathway in patients with attention-deficit and hyperactivity disorders. J Pineal Res 2011;51(4):394-9
   PubMed Web of Science ®Google Scholar
• Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008;13(1):90-8
   PubMed Web of Science ®Google Scholar
• De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006;17(7):291-8
   PubMed Web of Science ®Google Scholar
• De Leersnyder H, Bresson JL, de Blois MC, et al. Beta 1-adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J Med Genet 2003;40(1):74-8
   PubMed Web of Science ®Google Scholar
• Vanda: Tasimelteon-NASDAQ. 2014. Available from: http://www.nasdaq.com/aspx/call-transcript.aspx?StoryId=1591662&Title=vanda-pharmaceuticals-management-discusses-q2-2013-results-earnings-call-transcript
   Google Scholar
• Connor KM, Zhao X, Mahoney E, et al. Mk-6096, a dual orexin receptor antagonist, improves subjective measures of sleep and functioning in adults with primary insomnia. Neuropsychopharmacology 2011;36(Suppl 1S):S233
   Google Scholar
• Connor KM, Mahoney E, Jackson S, et al. A dual orexin receptor antagonist, mk-6096, in patients with primary insomnia: randomized controlled cross-over polysomnography study. Sleep Biol Rhythms 2011;9:332
   Google Scholar
• Chabi A, Zhang Y, Jackson S, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Minerva Neurosciences: Min-202. 2014. Available from: http://www.sleepreviewmag.com/2014/09/fda-completes-review-min-202-insomnia-us-clinical-trials-begin
   Google Scholar
• Eli Lilly. Ly2624803. 2013. Available from: http://clinicaltrials.gov/show/NCT01779830
   Google Scholar
• Tabuchi S, Tsunematsu T, Kilduff TS, et al. Influence of inhibitory serotonergic inputs to orexin/hypocretin neurons on the diurnal rhythm of sleep and wakefulness. Sleep 2013;36(9):1391-404
   PubMed Web of Science ®Google Scholar
• Neurim Pharmaceuticals. Piromelatine. 2013. Available from: http://www.neurim.com/news/2013-02-18/positive-phase-2-clinical-trial-results-of-piromelatine-for-the-treatment-of-insomnia
   Google Scholar
• Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev 2011;15(4):269-81
   PubMed Web of Science ®Google Scholar
• Teegarden BR, Al Shamma H, Xiong Y. 5-ht(2a) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008;8(11):969-76
   PubMed Web of Science ®Google Scholar
• Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21(Suppl 4):S703-9
   PubMed Web of Science ®Google Scholar
• Intracellular Therapies. ITI-007. Available from: http://www.intracellulartherapies.com/products-technology/iti-007.html
   Google Scholar